 CAMBRIDGE, Mass., Oct. 28, 2021 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. NASDAQ: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2021 financial results and provide a corporate update before market open on Thursday, November 4, 2021. Jounce Therapeutics management team will host a live conference call and webcast at 8:00 a.m. E.T. 